Drugs / Retinal pigment epitheliums
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03944239 | May 2021 → Dec 2026 expected | retinitis pigmentosa | Qi Zhou | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retinal pigment epitheliums | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03944239 ↗ |
| Modality | Cell therapy | “clinical human embryonic stem cell derived retinal pigment epitheliums” NCT03944239 ↗ |
| Route | Other | “into subretinal space” NCT03944239 ↗ |